LFSTHealthcare · Medical Care FacilitiesThe 11 Wall Street analysts covering Lifestance Health Group, Inc. hold a median 12-month price target of $13 — +7.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Lifestance Health Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Value (48): The shares cost a lot relative to the profits and assets behind them.
Size (24): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LFST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +7.0% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | BTIG | Maintains | Buy | $16 → $18 |
| 14 Aug 2026 | JP Morgan | Maintains | Neutral | $9.00 → $13 |
| 7 Aug 2026 | BTIG | Maintains | Buy | $15 → $16 |
| 24 July 2026 | BTIG | Maintains | Buy | $12 → $15 |
| 24 July 2026 | BTIG | Maintains | Buy | — |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $11 → $13 |
| 14 July 2026 | Barclays | Maintains | Overweight | — |
| 14 July 2026 | Barclays | Maintains | Overweight | $9.00 → $13 |
| 13 July 2026 | Keybanc | Maintains | Overweight | $11 → $13 |
| 13 July 2026 | Keybanc | Maintains | Overweight | — |
| 5 June 2026 | Goldman Sachs | Initiates | Neutral | — |
| 14 May 2026 | JP Morgan | Maintains | Neutral | — |
| 8 May 2026 | BTIG | Maintains | Buy | — |
| 6 Mar 2026 | Barclays | Maintains | Overweight | — |
| 26 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 26 Feb 2026 | Keybanc | Maintains | Overweight | — |
| 26 Feb 2026 | UBS | Maintains | Buy | — |
| 2 Feb 2026 | BTIG | Maintains | Buy | — |
| 12 Dec 2025 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LFST appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 8% of US stocks
Cheaper than 41% of US stocks
Cheaper than 32% of US stocks
Cheaper than 7% of US stocks
Higher than 76% of US stocks
Higher than 98% of US stocks
Higher than 43% of US stocks
Higher than 59% of US stocks
Higher than 55% of US stocks
Higher than 50% of US stocks
Higher than 61% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lifestance Health Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
LifeStance Health Group (LFST) shares rose 3.44% over one week, according to Zacks Investment Research. The article examines whether the stock could be considered a top pick for momentum investors.
Why it matters — A LFST watcher would care because the piece notes recent upward price momentum and evaluates the stock's potential appeal to momentum-focused investors.
Zacks Investment Research highlighted five low-leverage stocks, including Lifestance Health Group (LFST), that offer strong earnings growth and resilient balance sheets amid high oil prices and market volatility.
Why it matters — The mention positions LFST as a financially stable company with low leverage, which could appeal to investors seeking defensive holdings during uncertain market conditions.
LifeStance Health (LFST) was upgraded to a Zacks Rank #2 (Buy), reflecting increased optimism about the company's earnings prospects.
Why it matters — The upgrade signals improving analyst sentiment around LFST's earnings outlook, which could influence investor perception of the stock.
LifeStance Health Group's stock has reached a 52-week high. Zacks Investment Research examines the company's fundamentals to assess the potential for further gains.
Why it matters — The report evaluates whether LFST's fundamentals support continued upside after reaching a fresh 52-week high, a key consideration for those tracking the stock.
LifeStance Health released a survey of 1,000 women experiencing perimenopause or menopause, finding that one in three were unaware perimenopause can cause mental health symptoms such as anxiety and depression. The survey also indicated that a majority of women who seek mental healthcare during this stage find it helpful.
Why it matters — The survey underscores a gap in awareness that LifeStance can address, potentially driving demand for its mental health services among a large, underserved demographic.
The 11 Wall Street analysts covering Lifestance Health Group, Inc. have a median 12-month price target of $13, with estimates ranging from $12 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Lifestance Health Group, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lifestance Health Group, Inc. 96 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Lifestance Health Group, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +7.0% from the last close, and Ticker Nerd's factor model ranks Lifestance Health Group, Inc. 96 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lifestance Health Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $18 over the next 12 months.
Lifestance Health Group, Inc. returned +118.9% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Lifestance Health Group Inc. is a provider in the behavioral health care sector, delivering comprehensive psychological services across the United States.
The most recent item we track (Zacks Investment Research, 13 Aug 2026): "LifeStance Health Group (LFST) Is Up 3.44% in One Week: What You Should Know". LifeStance Health Group (LFST) shares rose 3.44% over one week, according to Zacks Investment Research. The article examines whether the stock could be considered a top pick for momentum investors.
Lifestance Health Group Inc. is a provider in the behavioral health care sector, delivering comprehensive psychological services across the United States. Specializing in mental health treatment, Lifestance Health focuses on psychiatrist and therapist services, catering to both children and adults. The company's core function is to facilitate access to mental health professionals, offering personalized care through in-person and telehealth visits, thereby enhancing accessibility and convenience for patients. With a diverse network of clinicians, Lifestance Health operates in collaboration with insurance providers and healthcare systems, embedding itself deeply within the community it serves. This integration underscores its role in addressing the growing demand for mental health support, influencing mental health policies and practices across various states. Established to improve the quality of care in the mental health sector, Lifestance Health Group plays a critical role by expanding its reach and setting benchmarks in patient-centered care, further cementing its market significance in the expanding behavioral health industry.
CEO Mr. David Patrick Bourdon · 8,542 employees · United States · https://lifestance.com